VRC-CHKVLP059-00-VP

BIOLOGICAL3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Chikungunya FeverChikungunya Virus InfectionViral Vaccines

Phase 1

Chikungunya Virus Vaccine Trial in Healthy Adults

CompletedNCT01489358

National Institute of Allergy and Infectious Diseases (NIAID)Chikungunya Fever, Chikungunya Virus Infection, Viral Vaccines

Start: 2011-12-31End: 2013-04-30Updated: 2016-07-25

Phase I Trial of Measles Vectored Chikungungya Vaccine

CompletedNCT03028441

National Institute of Allergy and Infectious Diseases (NIAID)Chikungunya Virus Infection

Start: 2017-05-30End: 2019-01-17Updated: 2020-11-27

Phase 2

Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults

CompletedNCT02562482

National Institute of Allergy and Infectious Diseases (NIAID)Chikungunya Virus Infection

Start: 2015-11-18End: 2018-03-06Updated: 2020-10-22

Related Papers

Chikungunya virus virus-like particle vaccine is well tolerated and immunogenic in chikungunya seropositive individuals

Vaccine2023-09-095 citations

Effect of a Chikungunya Virus–Like Particle Vaccine on Safety and Tolerability Outcomes

JAMA2020-04-14101 citations

Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial.

2014-08-14180 citations